LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Lantern Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary
Lantern Pharma Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Starlight Therapeutics Announces Inaugural Members Of Scientific Advisory Board
Brief: Lantern Pharma’S Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation In Glioblastoma From The FDA
U.S. STOCKS ON THE MOVE-US energy sector, gold miners, AeroVironment
U.S. STOCKS ON THE MOVE-Meta, US energy sector, gold miners
Lantern Pharma up on FDA's rare pediatric disease tag for cancer therapy
Brief: Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted To Lp-184 In Multiple Ultra Rare Children’S Cancers
Lantern Pharma Inc reports results for the quarter ended in June - Earnings Summary
Lantern Pharma Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Lantern Pharma Receives Certificate Of Patent From Japanese Patent Office For Composition Of Matter Covering Drug Candidate LP-284
Brief: Lantern Pharma Inc Files For Mixed Shelf Of Upto $150 Mln
Lantern Pharma Inc expected to post a loss of 43 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Lantern Pharma Receives Regulatory Approval To Expand Harmonic Clinical Trial For Non-Small Cell Lung Cancer
Lantern Pharma Inc reports results for the quarter ended in December - Earnings Summary
Lantern Pharma Inc expected to post a loss of 40 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Viatris, National Fuel Gas, Moderna
Brief: FDA Grants Lantern Pharma Orphan Drug Designation For Drug Candidate Lp-284 In High-Grade B-Cell Lymphomas (Hgbl)